These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23010649)

  • 1. Use of healthy volunteers drives clinical oncology drug development decision making.
    Iwamoto M; Iannone R; Wagner JA
    Clin Pharmacol Ther; 2012 Nov; 92(5):571-4. PubMed ID: 23010649
    [No Abstract]   [Full Text] [Related]  

  • 2. [Problems associated with molecular targeted drugs for cancer].
    Kawaishi M; Koizum F; Nishio K
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1373-9. PubMed ID: 17033223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
    Calvert AH; Plummer R
    Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finding the right dose.
    Ratain MJ
    Clin Adv Hematol Oncol; 2003 Sep; 1(9):517-8, 531. PubMed ID: 16258442
    [No Abstract]   [Full Text] [Related]  

  • 5. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multinomial phase II trial designs.
    Freidlin B; Dancey J; Korn EL; Zee B; Eisenhauer E
    J Clin Oncol; 2002 Jan; 20(2):599. PubMed ID: 11786592
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval).
    Morganroth J; Shah RR; Scott JW
    Clin Pharmacol Ther; 2010 Feb; 87(2):166-74. PubMed ID: 20010556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of tumor size response metrics to predict survival in oncology clinical trials.
    Bruno R; Mercier F; Claret L
    Clin Pharmacol Ther; 2014 Apr; 95(4):386-93. PubMed ID: 24419563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncology trials gear up for high-throughput sequencing.
    Mullard A
    Nat Rev Drug Discov; 2012 Apr; 11(5):339-40. PubMed ID: 22543457
    [No Abstract]   [Full Text] [Related]  

  • 10. Dose-toxicity models in oncology.
    Adamina M; Joerger M
    Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):201-11. PubMed ID: 21241201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New anticancer drugs: much ado about nothing?].
    Zimmermann S; Betticher D
    Rev Med Suisse; 2014 Apr; 10(425):788, 790-3. PubMed ID: 24791424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials.
    Paoletti X; Geoerger B; Doz F; Baruchel A; Lokiec F; Le Tourneau C
    Eur J Cancer; 2013 Jul; 49(10):2392-402. PubMed ID: 23540589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapeutic strategies for neoplasia.
    Talmadge JE
    Dev Biol Stand; 1992; 77():17-28. PubMed ID: 1426659
    [No Abstract]   [Full Text] [Related]  

  • 15. Newer phase II trial designs gaining ground.
    Benowitz S
    J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467
    [No Abstract]   [Full Text] [Related]  

  • 16. Oncology drug development: what is changing?
    Yancey MA
    Clin J Oncol Nurs; 2008 Oct; 12(5):713-5. PubMed ID: 18842527
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety biomarkers and the clinical development of oncology therapeutics: considerations for cardiovascular safety and risk management.
    Fingert H; Varterasian M
    AAPS J; 2006 Mar; 8(1):E89-94. PubMed ID: 16584137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.
    Park JW; Kerbel RS; Kelloff GJ; Barrett JC; Chabner BA; Parkinson DR; Peck J; Ruddon RW; Sigman CC; Slamon DJ
    Clin Cancer Res; 2004 Jun; 10(11):3885-96. PubMed ID: 15173098
    [No Abstract]   [Full Text] [Related]  

  • 19. Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?
    Gelibter AJ; Lonardi S; Di Segni S; Fontana A; Loupakis F; Cognetti F; Labianca R
    J Clin Oncol; 2006 Oct; 24(28):4668-9; author reply 4669. PubMed ID: 17008710
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of genomics on personalized cancer medicine.
    Arteaga CL; Baselga J
    Clin Cancer Res; 2012 Feb; 18(3):612-8. PubMed ID: 22298893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.